A glimpse into novel acylations and their emerging role in regulating cancer metastasis

Abstract

Metastatic cancer is a major cause of cancer-related mortality; however, the complex regulation process remains to be further elucidated. A large amount of preliminary investigations focus on the role of epigenetic mechanisms in cancer metastasis. Notably, the posttranslational modifications were found to be critically involved in malignancy, thus attracting considerable attention. Beyond acetylation, novel forms of acylation have been recently identified following advances in mass spectrometry, proteomics technologies, and bioinformatics, such as propionylation, butyrylation, malonylation, succinylation, crotonylation, 2-hydroxyisobutyrylation, lactylation, among others. These novel acylations play pivotal roles in regulating different aspects of energy mechanism and mediating signal transduction by covalently modifying histone or nonhistone proteins. Furthermore, these acylations and their modifying enzymes show promise regarding the diagnosis and treatment of tumors, especially tumor metastasis. Here, we comprehensively review the identification and characterization of 11 novel acylations, and the corresponding modifying enzymes, highlighting their significance for tumor metastasis. We also focus on their potential application as clinical therapeutic targets and diagnostic predictors, discussing the current obstacles and future research prospects.

Targeting Mitochondria for Cancer Treatment

“…The structure of modified protein dramatically changes due to a change in the isoelectric point of a protein (instead of one intrinsic positive charge, the lysine residue acquires a negative charge). Succinyl-CoA, formed as a result of the Krebs cycle or amino acid metabolism, serves as a donor for such posttranslational modification, which can be both enzymatic and non-enzymatic ([ 92 ], reviewed in [ 93 ]).…”